Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Comparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury.

Pais GM, Avedissian SN, O'Donnell JN, Rhodes NJ, Lodise TP, Prozialeck WC, Lamar PC, Cluff C, Gulati A, Fitzgerald JC, Downes KJ, Zuppa AF, Scheetz MH.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00079-19. doi: 10.1128/AAC.00079-19. Print 2019 Jul.

PMID:
30988153
2.

24-Hour Pharmacokinetic Relationships for Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury.

O'Donnell JN, Rhodes NJ, Lodise TP, Prozialeck WC, Miglis CM, Joshi MD, Venkatesan N, Pais G, Cluff C, Lamar PC, Briyal S, Day JZ, Gulati A, Scheetz MH.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00416-17. doi: 10.1128/AAC.00416-17. Print 2017 Nov.

3.

Dose, duration, and animal sex predict vancomycin-associated acute kidney injury in preclinical studies.

O'Donnell JN, Rhodes NJ, Miglis CM, Catovic L, Liu J, Cluff C, Pais G, Avedissian S, Joshi MD, Griffin B, Prozialeck W, Gulati A, Lodise TP, Scheetz MH.

Int J Antimicrob Agents. 2018 Feb;51(2):239-243. doi: 10.1016/j.ijantimicag.2017.08.012. Epub 2017 Aug 10. Review.

4.

Correction for Rhodes et al., Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats.

Rhodes NJ, Prozialeck WC, Lodise TP, Venkatesan N, O'Donnell JN, Pais G, Cluff C, Lamar PC, Neely MN, Gulati A, Scheetz MH.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e00185-17. doi: 10.1128/AAC.00185-17. Print 2017 Apr. No abstract available.

5.

Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats.

Rhodes NJ, Prozialeck WC, Lodise TP, Venkatesan N, O'Donnell JN, Pais G, Cluff C, Lamar PC, Neely MN, Gulati A, Scheetz MH.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5742-51. doi: 10.1128/AAC.00591-16. Print 2016 Oct. Erratum in: Antimicrob Agents Chemother. 2017 Mar 24;61(4):.

6.

Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology.

Michaud JP, Hallé M, Lampron A, Thériault P, Préfontaine P, Filali M, Tribout-Jover P, Lanteigne AM, Jodoin R, Cluff C, Brichard V, Palmantier R, Pilorget A, Larocque D, Rivest S.

Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1941-6. doi: 10.1073/pnas.1215165110. Epub 2013 Jan 15.

7.

Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.

Cluff CW.

Adv Exp Med Biol. 2010;667:111-23. doi: 10.1007/978-1-4419-1603-7_10.

PMID:
20665204
8.

Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.

Westaway SM, Brown SL, Fell SC, Johnson CN, MacPherson DT, Mitchell DJ, Myatt JW, Stanway SJ, Seal JT, Stemp G, Thompson M, Lawless K, McKay F, Muir AI, Barford JM, Cluff C, Mahmood SR, Matthews KL, Mohamed S, Smith B, Stevens AJ, Bolton VJ, Jarvie EM, Sanger GJ.

J Med Chem. 2009 Feb 26;52(4):1180-9. doi: 10.1021/jm801332q.

PMID:
19191554
9.

The 'Ethereal' nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics.

Bazin HG, Murray TJ, Bowen WS, Mozaffarian A, Fling SP, Bess LS, Livesay MT, Arnold JS, Johnson CL, Ryter KT, Cluff CW, Evans JT, Johnson DA.

Bioorg Med Chem Lett. 2008 Oct 15;18(20):5350-4. doi: 10.1016/j.bmcl.2008.09.060. Epub 2008 Sep 19.

PMID:
18835160
10.

Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge.

Cluff CW, Baldridge JR, Stöver AG, Evans JT, Johnson DA, Lacy MJ, Clawson VG, Yorgensen VM, Johnson CL, Livesay MT, Hershberg RM, Persing DH.

Infect Immun. 2005 May;73(5):3044-52.

11.

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents.

Baldridge JR, McGowan P, Evans JT, Cluff C, Mossman S, Johnson D, Persing D.

Expert Opin Biol Ther. 2004 Jul;4(7):1129-38. Review.

PMID:
15268679
12.

Structure-activity relationship of synthetic toll-like receptor 4 agonists.

Stöver AG, Da Silva Correia J, Evans JT, Cluff CW, Elliott MW, Jeffery EW, Johnson DA, Lacy MJ, Baldridge JR, Probst P, Ulevitch RJ, Persing DH, Hershberg RM.

J Biol Chem. 2004 Feb 6;279(6):4440-9. Epub 2003 Oct 21.

13.

Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.

Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge JR.

Expert Rev Vaccines. 2003 Apr;2(2):219-29. Review.

PMID:
12899573
14.

Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529.

Baldridge JR, Cluff CW, Evans JT, Lacy MJ, Stephens JR, Brookshire VG, Wang R, Ward JR, Yorgensen YM, Persing DH, Johnson DA.

J Endotoxin Res. 2002;8(6):453-8.

PMID:
12697089
15.

Antiischemic effect of monophosphoryl lipid A in conscious rabbits with hypercholesterolemia and atherosclerosis.

Szilvássy Z, Ferdinandy P, Cluff CW, Elliott GT.

J Cardiovasc Pharmacol. 1998 Aug;32(2):206-12.

PMID:
9700981
16.

Babesia bovis immunity. In vitro and in vivo evidence for IL-10 regulation of IFN-gamma and iNOS.

Goff WL, Johnson WC, Cluff CW.

Ann N Y Acad Sci. 1998 Jun 29;849:161-80.

PMID:
9668462
17.

Assessment of bovine mononuclear phagocytes and neutrophils for induced L-arginine-dependent nitric oxide production.

Goff WL, Johnson WC, Wyatt CR, Cluff CW.

Vet Immunol Immunopathol. 1996 Dec;55(1-3):45-62.

PMID:
9014305
18.

Reactive oxygen and nitrogen intermediates and products from polyamine degradation are Babesiacidal in vitro.

Johnson WC, Cluff CW, Goff WL, Wyatt CR.

Ann N Y Acad Sci. 1996 Jul 23;791:136-47.

PMID:
8784495
19.

Differential distribution of gamma delta T-cell receptor lymphocyte subpopulations in blood and spleen of young and adult cattle.

Wyatt CR, Madruga C, Cluff C, Parish S, Hamilton MJ, Goff W, Davis WC.

Vet Immunol Immunopathol. 1994 Mar;40(3):187-99.

PMID:
8160359
21.
22.
23.

Inhibition of macrophage-mediated antigen presentation by hemolysin-producing Listeria monocytogenes.

Cluff CW, Ziegler HK.

J Immunol. 1987 Dec 1;139(11):3808-12. Erratum in: J Immunol 1988 Apr 1;140(7):2477.

PMID:
3119719
24.
26.

Cyclosporine inhibits macrophage-mediated antigen presentation.

Palay DA, Cluff CW, Wentworth PA, Ziegler HK.

J Immunol. 1986 Jun 15;136(12):4348-53.

PMID:
3486899
27.

Pastoral enlightenment for seniors: do they need it? Do they want it?

Cluff CB.

J Am Geriatr Soc. 1984 Aug;32(8):609-13. No abstract available.

PMID:
6747172
28.

Informal support for disabled persons: a role for religious and community organizations.

Cluff CB, Cluff LE.

J Chronic Dis. 1983;36(12):815-20. No abstract available.

PMID:
6228559
29.

Supplemental Content

Support Center